About Cerus Corporation
https://www.cerus.comCerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
CEO
William M. Greenman
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 63
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:20.98M
Value:$57.49M
ARK INVESTMENT MANAGEMENT LLC
Shares:18.85M
Value:$51.65M
BLACKROCK INC.
Shares:13.89M
Value:$38.06M
Summary
Showing Top 3 of 209
About Cerus Corporation
https://www.cerus.comCerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $52.7M ▲ | $26.9M ▼ | $-19K ▲ | -0.04% ▲ | $-0 ▲ | $2.57M ▲ |
| Q2-2025 | $52.45M ▲ | $32.4M ▲ | $-5.71M ▲ | -10.88% ▲ | $-0.03 ▲ | $-3.15M ▲ |
| Q1-2025 | $43.24M ▼ | $31.28M ▲ | $-7.72M ▼ | -17.85% ▼ | $-0.04 ▼ | $-5.23M ▼ |
| Q4-2024 | $50.81M ▲ | $28.83M ▲ | $-2.52M ▲ | -4.96% ▲ | $-0.01 ▲ | $-66K ▲ |
| Q3-2024 | $46.02M | $27.16M | $-2.93M | -6.38% | $-0.02 | $-186K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $78.51M ▲ | $215.19M ▲ | $152.98M ▼ | $61.46M ▲ |
| Q2-2025 | $78.03M ▼ | $213.07M ▲ | $156.9M ▲ | $55.43M ▼ |
| Q1-2025 | $80.92M ▲ | $206.78M ▲ | $150.53M ▲ | $55.49M ▼ |
| Q4-2024 | $80.45M ▲ | $200.92M ▲ | $144.02M ▲ | $56.15M ▲ |
| Q3-2024 | $75.56M | $189.54M | $135.26M | $53.49M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-19K ▲ | $1.93M ▲ | $-2.51M ▼ | $320K ▲ | $-321K ▲ | $94K ▲ |
| Q2-2025 | $-5.71M ▲ | $-2.45M ▼ | $-1.09M ▲ | $-129K ▼ | $-3.45M ▼ | $-2.92M ▼ |
| Q1-2025 | $-7.72M ▼ | $-844K ▼ | $-1.19M ▲ | $1.07M ▲ | $-776K ▲ | $-956K ▼ |
| Q4-2024 | $-2.56M ▲ | $4.93M ▲ | $-7.29M ▼ | $746K ▲ | $-1.85M ▼ | $3.95M ▲ |
| Q3-2024 | $-2.93M | $4.07M | $4.82M | $60K | $9.1M | $3.35M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Government Contract | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $10.00M ▲ |
 Product | $50.00M ▲ | $40.00M ▼ | $50.00M ▲ | $50.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Europe Middle East And Africa | $10.00M ▲ | $20.00M ▲ | $10.00M ▼ | $20.00M ▲ |
 North America | $30.00M ▲ | $40.00M ▲ | $30.00M ▼ | $40.00M ▲ |
 Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
William M. Greenman
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 63
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:20.98M
Value:$57.49M
ARK INVESTMENT MANAGEMENT LLC
Shares:18.85M
Value:$51.65M
BLACKROCK INC.
Shares:13.89M
Value:$38.06M
Summary
Showing Top 3 of 209